On April 28, 2017, Zymeworks Inc. (NYSE/TSX: ZYME) priced and completed its proposed initial public offering (IPO) of 4,500,000 common shares at US $13 per share, the low end of the proposed US $13-16 range, for gross proceeds of US $58.5 million. (all figures in US dollars).
Zymeworks stock opened at $13.50, traded as high as $14.25 before closed at $13.00 on its first day trading on NYSE on April 28, 2017.
Certain of Zymeworks existing shareholders bought 3,017,690 (67%) of the 4,500,000 common shares offered for $39.2 million. Among the disclosed purchases, Eli Lilly and Company bought 365,000 shares, CTI Life Sciences Fund L.P. purchased 76,923 shares and Celgene Alpine Investment Co. LLP bought 270,000 shares.
Following the closing of the IPO, Zymeworks’ 5% shareholders are Eli Lilly 3,957,085 shares (15.9% on non-diluted basis); CTI Life Sciences Fund – 3,027,902 shares (12.1%); Ian Ihnatowycz/First Generation Capital – 1,566,256 shares (6.3%); and Celgene 1,39,483 shares (6.2%).
Zymeworks other shareholders include BDC Capital, Lumira Capital, Fonds de solidarité FTQ, Titan-Perc Ltd., Teralys Capital, Northleaf Venture Catalyst Fund, Brazyme LLC, Merlin Nexus, and MTS Securities.
photo credit: Zymeworks